E. Gerlach

发表

Comparative antimicrobial activity of piperacillin-tazobactam tested against more than 5000 recent clinical isolates from five medical centers. A reevaluation after five years.

R. Jones, K. Aldridge, S. Marshall, 1995, Diagnostic microbiology and infectious disease.

Simple inoculum standardizing system for antimicrobial disk susceptibility tests

M. Coyle, A. Barry, D. Amsterdam, 1979, Journal of clinical microbiology.

In vitro evaluation of cefixime (FK027, FR17027, CL284635): spectrum against recent clinical isolates, comparative antimicrobial activity, beta-lactamase stability, and preliminary susceptibility testing criteria.

L. Ayers, R. Jones, A. Barry, 1986, Diagnostic microbiology and infectious disease.

In vitro activity of cefpodoxime compared with other oral cephalosporins tested against 5556 recent clinical isolates from five medical centers.

Ronald N. Jones, P. Murray, R. Jones, 1993, Diagnostic microbiology and infectious disease.

Sucralfate significantly reduces ciprofloxacin concentrations in serum

J. Garrelts, P. Godley, J. Peterie, 1990, Antimicrobial Agents and Chemotherapy.

Ampicillin-sulbactam susceptibility testing criteria

D. Hardy, P. Fuchs, M. Pfaller, 1993, European Journal of Clinical Microbiology and Infectious Diseases.

Standardization of disk diffusion and agar dilution susceptibility tests for Neisseria gonorrhoeae: interpretive criteria and quality control guidelines for ceftriaxone, penicillin, spectinomycin, and tetracycline

P. Murray, R. Jones, J. Washington, 1989, Journal of clinical microbiology.

epidemiología y microbiología de infecciones debidas a Staphylococcus aureus en Misiones. primer estudio multicéntrico Epidemiology and microbiology of infections due to Staphylococcus aureus in misiones. first multicentered study

M. Robledo, A. Miranda, E. Gerlach, 2010 .

Serotyping herpes simplex virus isolated by enzyme-linked immunosorbent assays

M. Farkas, J. W. Bell, E. Gerlach, 1978, Journal of clinical microbiology.

Cefuroxime, a New Parenteral Cephalosporin: Collaborative In Vitro Susceptibility Comparison with Cephalothin Against 5,887 Clinical Bacterial Isolates

Ronald N. Jones, A. Barry, P. Fuchs, 1977, Antimicrobial Agents and Chemotherapy.

Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative.

G. Eliopoulos, M. Pfaller, R. Jones, 1993, Diagnostic microbiology and infectious disease.

Multicenter in vitro evaluation of SM-7338, a new carbapenem

R. Jones, K. Aldridge, A. Barry, 1989, Antimicrobial Agents and Chemotherapy.

In vitro activity of FCE 22101, imipenem, and ceftazidime against over 6,000 bacterial isolates and MIC quality control limits of FCE 22101

R. Jones, K. Aldridge, A. Barry, 1988, European Journal of Clinical Microbiology and Infectious Diseases.

In vitro comparison of E4868, a new trifluoroquinolone, with ciprofloxacin and temafloxacin tested against 5192 recent clinical isolates from five medical centers.

P. Murray, R. Jones, J. Washington, 1993, Diagnostic microbiology and infectious disease.

Multicenter in vitro evaluation of lomefloxacin (NY-198, SC-47111), including tests against nearly 7,000 bacterial isolates and preliminary recommendations for susceptibility testing.

R. Jones, J. Washington, K. Aldridge, 1988, Diagnostic microbiology and infectious disease.

Synthesis and Antibacterial Activity of Some 4-Substituted Benzenesulfonylhydrazones1

H. Zimmer, E. Gerlach, B. Gross, 1959 .

Cefotetan, a new cephamycin: comparison of in vitro antimicrobial activity with other cephems, beta-lactamase stability, and preliminary recommendations for disk diffusion testing

L. Ayers, R. Jones, A. Barry, 1982, Antimicrobial Agents and Chemotherapy.

In vitro comparison activity of OPC-17116, a new fluoroquinolone, against more than 5,000 recent clinical isolates from five medical centers.

P. Murray, R. Jones, J. Washington, 1993, Journal of chemotherapy.

Cefotaxime: in vitro activity and tentative interpretive standards for disk susceptibility testing

R. Jones, A. Barry, P. Fuchs, 1980, Antimicrobial Agents and Chemotherapy.

Methods of measuring zones of inhibition with the Bauer-Kirby disk susceptibility test

M. Coyle, A. Barry, C. Thornsberry, 1979, Journal of clinical microbiology.

Quality control limits for ampicillin, carbenicillin, mezlocillin, and piperacillin disk diffusion susceptibility tests: a collaborative study

L. Reller, R. Jones, A. Barry, 1981, Journal of clinical microbiology.

3-0-demethyl fortimicin A: In vitro activity and interpretive zone standards for disk diffusion susceptibility tests

R. Jones, A. Barry, C. Thornsberry, 1984, European Journal of Clinical Microbiology.

Interpretive standards for disk susceptibility tests with Sch 21420 and amikacin

R. Jones, A. Barry, C. Thornsberry, 1980, Antimicrobial Agents and Chemotherapy.

Gentamicin, tobramycin, and sisomicin disc susceptibility tests. Revised zone standards for interpretation.

R. Jones, A. Barry, C. Thornsberry, 1981, American journal of clinical pathology.

RO 23-6240 (AM-833), a new fluoroquinolone: in vitro antimicrobial activity and tentative disk diffusion interpretive criteria.

L. Ayers, R. Jones, A. Barry, 1987, Diagnostic microbiology and infectious disease.

In vitro activity of DJ-6783 (a keto carboxylic acid) compared with six other orally administered antimicrobial agents.

L. Ayers, R. Jones, A. Barry, 1986, Diagnostic microbiology and infectious disease.

Multilaboratory evaluation of an agar diffusion disk susceptibility test for rapidly growing anaerobic bacteria.

R. Jones, K. Aldridge, A. Bourgault, 1990, Reviews of infectious diseases.

Cefmetazole and trospectomycin in vitro susceptibility testing interpretive criteria and quality control guidelines for Neisseria gonorrheae.

P. Murray, F. Koontz, R. Jones, 1992, Diagnostic microbiology and infectious disease.

Moxalactam (LY127935), a new semisynthetic 1-oxa-beta-lactam antibiotic with remarkable antimicrobial activity: in vitro comparison with cefamandole and tobramycin

R. Jones, A. Barry, P. Fuchs, 1980, Antimicrobial Agents and Chemotherapy.

Quality control limits for the standard anaerobic reference agar dilution susceptibility test procedure of the National Committee for Clinical Laboratory Standards

R. Jones, A. Barry, P. Fuchs, 1989, Journal of clinical microbiology.

Comparative antimicrobial activity of aminothiazolyl methoxyimino cephalosporins against anaerobic bacteria, including 100 cefoxitin-resistant isolates.

R. Jones, K. Aldridge, A. Barry, 1987, Diagnostic microbiology and infectious disease.

Ceftizoxime: collaborative multiphased in-vitro evaluation including tentative interpretive standards for disc susceptibility tests, beta-lactamase stability, and inhibition.

R. Jones, A. Barry, P. Fuchs, 1982, The Journal of antimicrobial chemotherapy.

Collaborative evaluation of the microbial profile system for quantitative antimicrobial susceptibility testing

R. Jones, A. Barry, E. Gerlach, 1983, Journal of clinical microbiology.

Cefoperazone (T-1551), a new semisynthetic cephalosporin: comparison with cephalothin and gentamicin

R. Jones, A. Barry, P. Fuchs, 1980, Antimicrobial Agents and Chemotherapy.

Piperacillin (T-1220), a new semisynthetic penicillin: in vitro antimicrobial activity comparison with carbenicillin, ticarcillin, ampicillin, cephalothin, cefamandole and cefoxitin.

R. Jones, A. Barry, P. Fuchs, 1977, The Journal of antibiotics.

Microdilution antibiotic susceptibility test: examination of certain variables.

R. Tilton, E. Gerlach, L. Lieberman, 1973, Applied microbiology.

Ceftazidime, a pseudomonas-active cephalosporin: in-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility tests.

R. Jones, A. Barry, P. Fuchs, 1981, The Journal of antimicrobial chemotherapy.

Antimicrobial activity of Ro 15-8074, active metabolite of a new oral cephalosporin (Ro 15-8075), against 7,775 recent clinical isolates

L. Ayers, R. Jones, A. Barry, 1986, Antimicrobial Agents and Chemotherapy.

Cefmenoxime (SCE-1365), a new Cephalosporin: In Vitro Activity, Comparison with Other Antimicrobial Agents, Beta-Lactamase Stability, and Disk Diffusion Testing with Tentative Interpretive Criteria

Ronald N. Jones, A. Barry, P. Fuchs, 1981, Antimicrobial Agents and Chemotherapy.

Relative efficacy of tazobactam, sulbactam and clavulanic acid in enhancing the potency of ampicillin against clinical isolates ofEnterobacteriaceae

D. Hardy, P. Fuchs, M. Pfaller, 1993, European Journal of Clinical Microbiology and Infectious Diseases.

Comparison of fixed concentration and fixed ratio options for testing susceptibility of gram-negative bacilli to piperacillin and piperacillin/tazobactam

D. Hardy, A. Barry, P. Fuchs, 1992, European Journal of Clinical Microbiology and Infectious Diseases.

Tentative interpretive standards for disk susceptibility tests with moxalactam (LY127935)

R. Jones, A. Barry, C. Thornsberry, 1980, Antimicrobial Agents and Chemotherapy.

BL-S786, a new parenteral cephalosporin. II. In vitro antimicrobial activity comparison with six related cephalosporins.

R. Jones, A. Barry, P. Fuchs, 1977, The Journal of antibiotics.

Multicenter comparison of in vitro activities of FK-037, cefepime, ceftriaxone, ceftazidime, and cefuroxime

P. Murray, R. Jones, J. Washington, 1993, Antimicrobial Agents and Chemotherapy.

Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid

L. Ayers, R. Jones, A. Barry, 1984, Antimicrobial Agents and Chemotherapy.

Piperacillin/tazobactam (YTR 830) combination. Comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strains.

R. Jones, K. Aldridge, P. Fuchs, 1989, Diagnostic microbiology and infectious disease.

Antimicrobial activity of cefpirome. An update compared to five third-generation cephalosporins against nearly 6000 recent clinical isolates from five medical centers.

R. Jones, K. Aldridge, P. Fuchs, 1991, Diagnostic microbiology and infectious disease.

MIC quality control guidelines for Haemophilus susceptibility tests using cefdinir (FK482), cefepime, cefetamet, cefpirome, ceftibuten, fleroxacin, temafloxacin, clarithromycin, RP59500, and trospectomycin

P. Murray, F. Koontz, R. Jones, 1992, Journal of clinical microbiology.

Fortimicin A: collaborative in vitro susceptibility. Comparison with amikacin and gentamicin against 11,840 clinical bacterial isolates

R. Jones, A. Barry, P. Fuchs, 1979, Antimicrobial Agents and Chemotherapy.

1-N-(S-3-amino-2-hydroxypropionyl) gentamicin B (Sch 21420): A collaborative in vitro susceptibility comparison with amikacin and gentamicin against 12,984 clinical bacterial isolates

Ronald N. Jones, A. Barry, P. Fuchs, 1978, Current Microbiology.

Ticarcillin: a collaborative in vitro comparison with carbenicillin against over 9,000 clinical bacterial isolates

R. Jones, A. Barry, P. Fuchs, 1977, The American journal of the medical sciences.

BL-S786, A NEW PARENTERAL CEPHALOSPORIN. I

Ronald N. Jones, A. Barry, P. Fuchs, 1977 .

Cefpiramide: comparative in-vitro activity and β-lactamase stability

Ronald N. Jones, L. Ayers, A. Barry, 1985 .

Validation of NCCLS macrolide (azithromycin, clarithromycin, and erythromycin) interpretive criteria for Haemophilus influenzae tested with the Haemophilus test medium. National Committee for Clinical Laboratory Standards.

J. Hindler, G. Doern, R. Jones, 1994, Diagnostic microbiology and infectious disease.

Cefaclor and cefatrizine, new investigational orally administered cephalosporins. In-vitro collaborative evaluation against clinical bacterial isolates and comparison with related antimicrobics.

R. Jones, A. Barry, P. Fuchs, 1979, American journal of clinical pathology.

Rosamicin: in vitro activity comparison with erythromycin and other antibiotics against clinical isolates from the genito-urinary tract and Neisseria meningitidis.

R. Jones, A. Barry, P. Fuchs, 1979, The Journal of antibiotics.

Disk diffusion testing, quality control guidelines, and antimicrobial spectrum of HR810, a fourth-generation cephalosporin, in clinical microbiology laboratories

L. Ayers, R. Jones, A. Barry, 1984, Journal of clinical microbiology.

Immunoglobulin response to rabies vaccine in man.

R. Rubin, P. Gough, R. Sikes, 1971, Lancet.

Antimicrobial activity and spectrum of cefoperazone against recent clinical isolates.

R. Jones, A. Barry, P. Fuchs, 1980, Clinical therapeutics.

Cefuroxime, an in vitro Comparison with Six Other Cephalosporins

R. Jones, A. Barry, P. Fuchs, 1977, Proceedings of the Royal Society of Medicine.

Increased production of beta-lactamase under anaerobic conditions in some strains of Escherichia coli

A. Rashtchian, E. Gerlach, G. Miller, 1979, Antimicrobial Agents and Chemotherapy.

In vitro activity of ampicillin, amoxicillin, ampicillin-sulbactam, and amoxicillin-clavulanic acid against consecutive clinical isolates of Enterobacteriaceae.

D. Hardy, A. Barry, P. Fuchs, 1993, Diagnostic microbiology and infectious disease.

Antimicrobial activity of HR810 against 419 strict anaerobic bacteria

R. Jones, E. Gerlach, 1985, Antimicrobial Agents and Chemotherapy.

Multicenter clinical laboratory evaluation of a beta-lactamase disk assay employing a novel chromogenic cephalosporin, S1

G. Doern, R. Jones, J. Washington, 1995, Journal of clinical microbiology.

Quality control limits for microdilution susceptibility tests with aztreonam, imipenem, ceftriaxone, ceftazidime, ceftizoxime, cefuroxime, and cefonicid.

L. Ayers, R. Jones, A. Barry, 1987, Diagnostic microbiology and infectious disease.

In vitro activity of carumonam (RO 17-2301), BMY-28142, aztreonam, and ceftazidime against 7,620 consecutive clinical bacterial isolates.

L. Ayers, R. Jones, A. Barry, 1986, Diagnostic microbiology and infectious disease.

In-vitro activity of five β-lactam/β-lactamase inhibitor combinations against consecutive isolates of the Enterobacteriaceae and Pseudomonas aeruginosa

D. Hardy, A. Barry, P. Fuchs, 1994 .

Error rates in cefoperazone and cefoperazone-sulbactam disk tests withenterobacteriaceae andPseudomonas aeruginosa

D. Hardy, A. Barry, P. Fuchs, 1992, European Journal of Clinical Microbiology and Infectious Diseases.

Quality control limits for microdilution susceptibility tests with norfloxacin

L. Ayers, A. Barry, P. Fuchs, 1987, Journal of clinical microbiology.

Effect of clavulanic acid on the susceptibility of clinical anaerobic bacteria to ticarcillin: a multicenter study.

R. Jones, K. Aldridge, A. Barry, 1988, Diagnostic microbiology and infectious disease.

Multilaboratory evaluation of the in vitro activity of 13 beta-lactam antibiotics against 1474 clinical isolates of aerobic and anaerobic bacteria.

P. Murray, R. Jones, P. Fuchs, 1993, Diagnostic microbiology and infectious disease.

Antimicrobial activity of Ro 19-5247 (T-2525), a new oral cephalosporin, tested against 7,745 recent clinical isolates.

L. Ayers, R. Jones, A. Barry, 1987, Diagnostic microbiology and infectious disease.

Interpretive criteria and quality control guidelines for lomefloxacin and meropenem in susceptibility tests of Haemophilus influenzae using Haemophilus test medium.

M. Pfaller, F. Koontz, R. Jones, 1992, Diagnostic microbiology and infectious disease.

BL-S786, a new parenteral cephalosporin. I. A collaborative in vitro susceptibility comparison to cephalothin against 5,762 clinical bacterial isolates.

R. Jones, A. Barry, P. Fuchs, 1977, The Journal of antibiotics.

Interpretive criteria, quality control guidelines, and drug stability studies for susceptibility testing of cefotaxime, cefoxitin, ceftazidime, and cefuroxime against Neisseria gonorrhoeae.

P. Murray, R. Jones, J. Washington, 1990, Diagnostic microbiology and infectious disease.

Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates

A. Barry, P. Fuchs, M. Pfaller, 1991, Antimicrobial Agents and Chemotherapy.

MIC and disk diffusion quality control guidelines for Neisseria gonorrhoeae susceptibility tests of cefdinir, cefetamet, CI-960, fleroxacin, lomefloxacin, and temafloxacin

P. Murray, F. Koontz, R. Jones, 1992, Journal of clinical microbiology.

Development of Neisseria gonorrhoeae in vitro susceptibility test methods for cefixime including quality control guidelines.

P. Murray, M. Pfaller, F. Koontz, 1991, Diagnostic microbiology and infectious disease.

Standardization ofDiskDiffusion andAgarDilution Susceptibility Tests forNeisseria gonorrhoeae: Interpretive Criteria andQuality Control Guidelines forCeftriaxone, Penicillin, Spectinomycin, andTetracycline

Ronald N. Jones, E. Gerlach, T. Gavan, 1989 .

Interpretive criteria and quality control guidelines for Neisseria gonorrhoeae susceptibility test standardization for cefotetan

P. Murray, M. Pfaller, F. Koontz, 1991, Journal of clinical microbiology.

Interpretive Criteria andQuality Control Guidelines forNeisseria gonorrhoeae Susceptibility TestStandardization forCefotetan

P. Murray, M. Pfaller, F. Koontz, 1991 .

Interpretive criteria and quality control parameters for determining bacterial susceptibility to fosfomycin tromethamine

F. Tenover, L. Reller, D. Hardy, 1993, European Journal of Clinical Microbiology and Infectious Diseases.

Optimal cefotaxime dosing for gram-negative bacteremia: effective trough serum bactericidal titers and drug concentrations 8 and 12 hr after 1- or 2-gm infusions.

R. Jones, H. Goodpasture, J. Peterie, 1988, Diagnostic microbiology and infectious disease.

In vitro activity of apalcillin compared with those of piperacillin and carbenicillin against 6,797 bacterial isolates from four separate medical centers

L. Ayers, R. Jones, A. Barry, 1984, Antimicrobial Agents and Chemotherapy.

Ticarcillin, carbenicillin and BL-P1908. In vitro comparison of three anti-pseudomonal semisynthetic penicillins.

R. Jones, A. Barry, P. Fuchs, 1977, The Journal of antibiotics.

Piperacillin susceptibility tests by the single-disk agar diffusion technique

R. Jones, A. Barry, C. Baker, 1979, Antimicrobial Agents and Chemotherapy.

Quality control guidelines for Haemophilus test medium MIC susceptibility tests with cefmetazole, cefpodoxime, CI-960 (PD127391, AM-1090), and RU29246.

M. Pfaller, F. Koontz, R. Jones, 1991, Journal of Antimicrobial Chemotherapy.

In vitro Inhibition of Migration of Leukocytes by Old Tuberculin (OT) as an Indicator of Active Tuberculosis.

C. Thornsberry, E. Gerlach, M. Schesago, 1964 .

The effect of chemotherapy on the tuberculin sensitivity of leukocytes from tuberculous patients.

H. E. Hall, E. Gerlach, M. Scherago, 1960, The American review of respiratory disease.

The re-evaluation of the NCCLS ampicillin susceptibility tests with Haemophilus test medium: New interpretive criteria for the disk diffusion method

Ronald N. Jones, G. Doern, J. Hindler, 1992 .

Cefdinir (FK482), an orally administered cephalosporin in vitro activity comparison against recent clinical isolates from five medical centers and determination of MIC quality control guidelines.

P. Murray, M. Pfaller, F. Koontz, 1992, Diagnostic microbiology and infectious disease.

In-vitro comparison of DU-6859a, a novel fluoroquinolone, with other quinolones and oral cephalosporins tested against 5086 recent clinical isolates.

P. Murray, R. Jones, J. Washington, 1993, The Journal of antimicrobial chemotherapy.

Ticarcillin and ticarcillin-clavulanic acid susceptibility tests: error rates for disk tests with consecutively isolated members of the family Enterobacteriaceae

D. Hardy, A. Barry, P. Fuchs, 1992, Antimicrobial Agents and Chemotherapy.

Comparison of fixed concentration and fixed ratio options for dilution susceptibility testing of gram-negative bacilli to ampicillin and ampicillin/sulbactam

D. Hardy, A. Barry, P. Fuchs, 1993, European Journal of Clinical Microbiology and Infectious Diseases.

Revised disk diffusion interpretive criteria for cefaclor, loracarbef, cefprozil and cefixime when testingHaemophilus influenzae on Haemophilus Test Medium

J. Hindler, G. Doern, R. Jones, 1994, European Journal of Clinical Microbiology and Infectious Diseases.

Quality control limits for disk diffusion and broth microdilution susceptibility tests with Haemophilus test medium.

P. Murray, G. Doern, J. Jorgensen, 1991, Diagnostic microbiology and infectious disease.